Breaking up the CD8+ T cell: Treg pas de deux
Cancer Cell · 2024
DOI: 10.1016/j.ccell.2024.05.016 ↗Kurz gefasst
Kommentar in der Zeitschrift Cancer Cell, 2024. Verfasst von Chenyu Zhang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Immunology and Molecular Medicine, Department of Molecular and Cell Biology, University of California Berkeley, Berkeley, CA, USA. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, T-Lymphocytes, Regulatory. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 10 Literaturangaben. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Checkpoint blockade immunotherapies, such as anti-programmed death-1 (PD-1), unleash anti-tumor CD8+ T cell responses but may also induce immunosuppressive regulatory T cells (Tregs). In this issue of Cancer Cell, Geels et al. uncover that anti-PD-1 leads to Treg expansion via interleukin-2 (IL-2)-producing CD8+ T cells. Combining anti-PD-1 with anti-ICOSL interrupts this crosstalk, thereby enhancing tumor control.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Immunology and Molecular Medicine, Department of Molecular and Cell Biology, University of California Berkeley, Berkeley, CA, USA.
- Division of Immunology and Molecular Medicine, Department of Molecular and Cell Biology, University of California Berkeley, Berkeley, CA, USA. Electronic address: dupage@berkeley.edu.
Förderung
- NCI NIH HHS
Zitieren
APA
Zhang, C., Bockman, A., & DuPage, M. (2024). Breaking up the CD8+ T cell: Treg pas de deux. Cancer Cell. https://doi.org/10.1016/j.ccell.2024.05.016
Vancouver
Zhang C, Bockman A, DuPage M. Breaking up the CD8+ T cell: Treg pas de deux. Cancer Cell. 2024. doi:10.1016/j.ccell.2024.05.016
BibTeX
@article{Zhang2024,
author = {Zhang, Chenyu and Bockman, Alissa and DuPage, Michel},
title = {Breaking up the CD8+ T cell: Treg pas de deux},
journal = {Cancer Cell},
year = {2024},
doi = {10.1016/j.ccell.2024.05.016}
}
EUVIMED